The Roche BRAF inhibitor, compound Ia, is designed to address the limitations of existing BRAFi/MEKi inhibitor combinations. It is a RAF paradox breaker (see belvarafenib) and is brain penetrant, offering the potential to address several mechanisms of resistance to approved agents and potentially reducing the need for MEKi combination [...]
< 1 minute read
Dec. 20, 2021
A Brain-Penetrant, Paradox-Breaking BRAF Inhibitor from Roche
"compound Ia"
oral BRAF inhibitor, brain penetrant effective in A375-derived mouse models from prior paradox inducing BRAF inhibitors Clinical Cancer Research Roche
Reviewer:
Loading...
